Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vume... Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. Mehr anzeigen
"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico PR Newswire TOKYO and CAMBRIDGE, Mass., Dec. 4, 2024 TOKYO and CAMBRIDGE, Mass., Dec. 4, 2024...
"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea PR Newswire TOKYO and CAMBRIDGE, Mass., Nov. 27, 2024 TOKYO and CAMBRIDGE, Mass., Nov. 27, 2024...
Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease PR Newswire TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 TOKYO and CAMBRIDGE, Mass...
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -3.32 | -2.18220060471 | 152.14 | 156.37 | 147.65 | 1160904 | 151.50807251 | CS |
| 4 | -0.025 | -0.0167959958346 | 148.845 | 156.37 | 145.24 | 1473928 | 149.45786093 | CS |
| 12 | -40.98 | -21.5911485774 | 189.8 | 190.4 | 145.24 | 1517002 | 161.91894882 | CS |
| 26 | -81.24 | -35.3125271668 | 230.06 | 236.48 | 145.24 | 1279364 | 180.43060168 | CS |
| 52 | -98.18 | -39.7489878543 | 247 | 252.17 | 145.24 | 1212176 | 200.10628307 | CS |
| 156 | -76.48 | -33.9458499778 | 225.3 | 319.76 | 145.24 | 1160640 | 234.12512381 | CS |
| 260 | -145.97 | -49.5166050409 | 294.79 | 468.2499 | 145.24 | 1313786 | 262.41181119 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
